Parabilis Medicines (PBLS) Form 3 details officer stock option awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Parabilis Medicines, Inc. officer Rohin Mhatre filed an initial Form 3 reporting holdings of stock options to purchase the company’s common stock. The filing lists three option grants with different exercise prices, share amounts and expiration dates.

One option covers 243,680 underlying shares at an exercise price of $3.14 per share expiring on February 17, 2036. Two additional options cover 181,948 and 38,988 underlying shares at an exercise price of $1.48 per share, both expiring on March 27, 2034. Footnotes explain that these options vest in monthly installments over multi‑year periods, contingent on continued service.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Mhatre Rohin

Role See Remarks

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 38,988 shares (Direct, null)

Footnotes (1)

The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from January 1, 2024, subject to the Reporting Person's continued service on each such vesting date. 25% of the shares subject to this option vested and became exercisable on October 23, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option underlying shares: 243,680 shares Exercise price: $3.14 per share Option underlying shares: 181,948 shares +3 more

6 metrics

Option underlying shares 243,680 shares Underlying common stock for option at $3.14 exercise price

Exercise price $3.14 per share Stock option on 243,680 underlying shares

Option underlying shares 181,948 shares Underlying common stock for option at $1.48 exercise price

Option underlying shares 38,988 shares Underlying common stock for option at $1.48 exercise price

Expiration date February 17, 2036 Expiration for $3.14 stock option grant

Expiration date March 27, 2034 Expiration for $1.48 stock option grants

Key Terms

Stock Option (right to buy), underlying security, exercise price, vesting

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

underlying security financial

"underlying_security_title: Common Stock"

exercise price financial

"conversion_or_exercise_price: 3.1400 and 1.4800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to this option shall vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding Insider Trading Forms →

06/09/2026 - 09:17 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mhatre Rohin

(Last)

(First)

(Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE

MASSACHUSETTS

02140

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	03/27/2034	Common Stock	38,988	$1.48	D
Stock Option (right to buy)	⁽²⁾	03/27/2034	Common Stock	181,948	$1.48	D
Stock Option (right to buy)	⁽³⁾	02/17/2036	Common Stock	243,680	$3.14	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from January 1, 2024, subject to the Reporting Person's continued service on each such vesting date.

2. 25% of the shares subject to this option vested and became exercisable on October 23, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

3. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney; Title: Chief Technical Operations Officer

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Parabilis Medicines (PBLS) disclose in Rohin Mhatre’s Form 3?

Parabilis Medicines reports that officer Rohin Mhatre holds three stock option awards for its common stock. The Form 3 lists each option’s exercise price, number of underlying shares, expiration dates and vesting schedules tied to his continued service with the company.

How many Parabilis Medicines (PBLS) shares are covered by Rohin Mhatre’s options?

The Form 3 shows options over 243,680 underlying common shares at one exercise price, plus separate options over 181,948 and 38,988 underlying shares. These positions represent potential future share ownership if the options vest and are exercised.

What are the exercise prices of Rohin Mhatre’s Parabilis Medicines (PBLS) options?

Mhatre’s disclosed options have exercise prices of $3.14 and $1.48 per share. The largest grant is priced at $3.14, while two additional grants are priced at $1.48, providing different potential entry levels if exercised in the future.

When do Rohin Mhatre’s Parabilis Medicines (PBLS) options expire?

The option covering 243,680 underlying shares expires on February 17, 2036. The options covering 181,948 and 38,988 underlying shares each expire on March 27, 2034, giving long-dated potential for exercise if vesting and service conditions are met.

How do Rohin Mhatre’s Parabilis Medicines (PBLS) options vest?

Footnotes state some options vest in forty-eight equal monthly installments starting on specific dates, while another vests 25% at an initial date, then in thirty-six monthly installments. All vesting depends on Mhatre’s continued service with Parabilis Medicines on each vesting date.

Does Parabilis Medicines (PBLS) Form 3 show any recent insider buying or selling?

The Form 3 lists option holdings but does not report open‑market purchases or sales. Transactions are classified as holdings, with no buy or sell transaction codes indicated, so the filing mainly establishes Mhatre’s existing derivative positions in company stock.